MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
about
miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2MiR-101 Targets the EZH2/Wnt/β-Catenin the Pathway to Promote the Osteogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells.Autophagy-Regulating microRNAs and CancermiR-195 inhibits cell proliferation via targeting AEG-1 in hepatocellular carcinoma.Identification of miR-101-3p targets and functional features based on bioinformatics, meta-analysis and experimental verification in hepatocellular carcinoma.Upregulation of miR-101 enhances the cytotoxic effect of anticancer drugs through inhibition of colon cancer cell proliferation.Expression profiling of serum microRNA-101 in HBV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.MicroRNAs associated with HBV infection and HBV-related HCC.Drugs acting on homeostasis: challenging cancer cell adaptation.Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4.miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells.Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancerEZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma.MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma.The Circular RNA Cdr1as Act as an Oncogene in Hepatocellular Carcinoma through Targeting miR-7 ExpressionEZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cellsDNA methylation mediated silencing of microRNA-145 is a potential prognostic marker in patients with lung adenocarcinoma.Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis.Mechanisms of doxorubicin resistance in hepatocellular carcinomaStathmin1 increases radioresistance by enhancing autophagy in non-small-cell lung cancer cells.Gene expression analysis of biopsy samples reveals critical limitations of transcriptome-based molecular classifications of hepatocellular carcinoma.Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors.MicroRNA-29c-5p suppresses gallbladder carcinoma progression by directly targeting CPEB4 and inhibiting the MAPK pathway.MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy.Oncogenic and tumor suppressive roles of microRNAs in apoptosis and autophagy.The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment.Autophagy and microRNA dysregulation in liver diseases.miR-709 up-regulated in hepatocellular carcinoma, promotes proliferation and invasion by targeting GPC5.Genetic and epigenetic alterations in hepatitis B virus-associated hepatocellular carcinoma.miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies.Clinical relevance of autophagic therapy in cancer: Investigating the current trends, challenges, and future prospects.Insights into the involvement of noncoding RNAs in 5-fluorouracil drug resistance.miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.Methylation-associated silencing of miR-200b facilitates human hepatocellular carcinoma progression by directly targeting BMI1.miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer.MiR-335 acts as a potential tumor suppressor miRNA via downregulating ROCK1 expression in hepatocellular carcinoma.Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatmentExpression Profiling of Cellular MicroRNA in Asymptomatic HBsAg Carriers and Chronic Hepatitis B Patients.
P2860
Q28606716-10FA2BA1-4E87-40FF-B556-7299DA335971Q30275413-66348E1C-461E-436A-A9C5-4724AB262C2AQ33572337-414CBC93-B856-41CF-93D9-3A049FC55960Q33685465-F6CBF698-D7FC-4609-9EA6-67982D51FFA8Q33733091-D99AE8A2-8479-4681-AE59-E97129E1404CQ33858033-7000AADC-6711-4B41-93F4-74C166662D47Q34028475-8C0D5E64-B0E9-4DD4-ABB7-D20C87AA8E70Q34284404-B2E920DC-BE6A-4C48-920E-2D606BD21939Q34500113-DC6D42F3-26C2-4507-920C-A4C08BAA54FCQ34982573-109C65ED-3540-4EAD-B407-1D16B7D25CE5Q35557027-26DC7117-B506-4073-93FC-0922DE63F8B9Q35740123-39D98139-4054-47A9-AE6D-EB952F902A26Q35787278-6F7C9A30-FACF-4023-8DA6-C69030E1A754Q35922940-18AC4109-BCEE-4517-9F20-D10C967AE9BAQ36071336-E728F20F-F84D-4669-BC4D-1739C769DC4BQ36212878-FB979538-A9CE-4B82-BC48-1F3D115624A1Q36298188-04E5DCE1-5323-4D27-8C57-C6D70CCC6997Q36545734-14567D5C-1910-4975-9F7D-C6CD3689FF9EQ36687760-68E15367-DAC1-454D-ABA5-2DE5E7E4F82BQ36872856-11C17D6F-BEBB-4CE4-A4CF-7869FEB71E68Q37002076-B8DFD6C5-568B-48BF-9004-3F450AD27F23Q37407115-DA506326-23B5-4C08-B22E-09257985B313Q37691434-FB709DF2-671E-4849-8F48-0BA89B7E8AA7Q37693388-95052057-C2F3-49B9-B6E2-3CD8D13E00BDQ37694818-56B5205E-B512-43EE-B0E4-CA60BAB74292Q37744911-A230CE38-9493-4134-BDB3-95E869921374Q38213627-E76130A9-B2F8-40D1-8304-3B061CA9D8C5Q38213933-68D28188-6EDA-4313-BE24-16DA41771647Q38228503-06BA06D2-C592-4755-BFB7-4C806E5677A1Q38300178-18C67D0D-9065-416F-9A2E-ED250DBEBFD8Q38415638-4FC34775-971D-4E1B-AA66-7093AAB0FA5AQ38476564-EC5B0F2D-5D8E-4FCA-B340-3C7D5C7674D1Q38689955-3C2C2E67-D6E1-40A2-82E7-47F0BFD69D17Q38734494-BD854788-605F-4B19-A542-07E6C07A1B65Q38752301-13CEA2A8-AF22-44D2-82C8-B0075419F348Q38790804-D344F4FD-E2E4-4C10-ABF8-757C579302B0Q38952951-3AF4D27B-ACA4-4925-84B2-5810EFE95D11Q39025811-804C70D3-D447-4EED-B944-E69455F92D51Q40014635-CDB7D88A-71B0-4E62-8298-354242B61D87Q40039691-D5392838-06EA-425F-9F72-F6C3889E1BBF
P2860
MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
MicroRNA-101 inhibits human he ...... d cytostatic drug sensitivity.
@ast
MicroRNA-101 inhibits human he ...... d cytostatic drug sensitivity.
@en
type
label
MicroRNA-101 inhibits human he ...... d cytostatic drug sensitivity.
@ast
MicroRNA-101 inhibits human he ...... d cytostatic drug sensitivity.
@en
prefLabel
MicroRNA-101 inhibits human he ...... d cytostatic drug sensitivity.
@ast
MicroRNA-101 inhibits human he ...... d cytostatic drug sensitivity.
@en
P2093
P1476
MicroRNA-101 inhibits human he ...... d cytostatic drug sensitivity.
@en
P2093
Arnold Radtke
Gernot M Kaiser
Hartmut H Schmidt
Iyad Kabar
Speranta Iacob
Susanne Beckebaum
P304
P356
10.1016/J.JHEP.2013.10.028
P577
2013-11-06T00:00:00Z